Der Hautarzt

, Volume 59, Issue 10, pp 841–852 | Cite as

Atopisches Ekzem im Erwachsenenalter

CME Weiterbildung • Zertifizierte Fortbildung

Zusammenfassung

Die Prävalenz des atopischen Ekzems (AE) im Erwachsenenalter beträgt 1–3%. Positive Familienanamnese, früher Erkrankungsbeginn, schwerer Krankheitsverlauf im Kindesalter und Komorbidität mit anderen Erkrankungen des atopischen Formenkreises sind Prädiktoren für die Persistenz des AE bis ins Erwachsenenalter, außerdem wird von genetischen Risikofaktoren ausgegangen. Auch eine Erstmanifestation des AE im Erwachsenenalter ist möglich. Stress und psychische Belastung wurden unabhängig vom Geschlecht als wichtigster Schubfaktor des AE eingestuft. Bisher steht keine kausale Therapie für das AE zur Verfügung. Die Basis der symptomatischen Therapie besteht aus einer stadiengerechten pflegenden und rückfettenden Lokaltherapie, antiseptischen Externa und Antipruriginosa. Bei Exazerbation kommen topische Kortikosteroide und/oder topische Calcineurininhibitoren zum Einsatz. Für erwachsene Patienten mit schwerem AE, die mit den zur Verfügung stehenden topischen Therapieoptionen nicht ausreichend effektiv behandelt werden können, werden neben Antihistaminika und ggf. Antibiotika eine UV-Therapie und immunsuppressive bzw. immunmodulatorische Systemtherapeutika empfohlen.

Schlüsselwörter

Atopisches Ekzem Erwachsene Prävalenz Schubfaktoren Therapie 

Atopic exzema in adulthood

Abstract

The prevalence of atopic eczema (AE) in adulthood is 1–3%. A positive family history, early disease onset, a severe disease course in childhood, and comorbidity of other disorders among the circle of atopic forms are predictors for persistence of AE into adulthood; furthermore, genetic risk factors are assumed. Initial manifestation of AE in adulthood is also possible. Stress/psychological burden have been classified as the most important triggering factor of AE. To date a causal therapy for AE is not available. The basis of symptomatic treatment consists of stage-appropriate skin care and moisturizing local therapy, antiseptic agents for external application, and antipruritic agents. In cases of exacerbation topical corticosteroids and/or topical calcineurine inhibitors are used. For the adult patient with severe AE who cannot be treated effectively with the topical treatment options available, UV therapy and immunosuppressive or immunomodulatory systemic drugs are recommended.

Keywords

Atopic eczema Adults Prevalence Triggering factors Therapy 

Literatur

  1. 1.
    Herd RM, Tidman MJ, Prescott RJ, Hunter JA (1996) Prevalence of atopic eczema in the community: the Lothian Atopic Dermatitis study. Br J Dermatol 135: 18–19PubMedCrossRefGoogle Scholar
  2. 2.
    Vartiainen E, Petays T, Haahtela T et al. (2002) Allergic diseases, skin prick test responses, and IgE levels in North Karelia, Finland, and the Republic of Karelia, Russia. J Allergy Clin Immunol 109: 643–648PubMedCrossRefGoogle Scholar
  3. 3.
    Muto T, Hsieh SD, Sakurai Y et al. (2003) Prevalence of atopic dermatitis in Japanese adults. Br J Dermatol 148: 117–121PubMedCrossRefGoogle Scholar
  4. 4.
    Ingordo V, D’Andria G, D’Andria C (2003) Adult-onset atopic dermatitis in a patch test population. Dermatology 206: 197–203PubMedCrossRefGoogle Scholar
  5. 5.
    Williams H, Wüthrich B (2000) The natural history of atopic dermatitis. In: Williams H (ed) Atopic dermatitis: the epidemiology, causes, and prevention of atopic eczema. Cambridge University Press, Cambridge, UK, pp 41–59Google Scholar
  6. 6.
    Williams HC (2000) Epidemiology of atopic dermatitis. Clin Exp Dermatol 25: 522–529PubMedCrossRefGoogle Scholar
  7. 7.
    Dennis R, Caraballo L, Garcia E et al. (2004) Asthma and other allergic conditions in Colombia: a study in 6 cities. Ann Allergy Asthma Immunol 93: 568–574PubMedCrossRefGoogle Scholar
  8. 8.
    Yemaneberhan H, Flohr C, Lewis SA et al. (2004) Prevalence and associated factors of atopic dermatitis symptoms in rural and urban Ethiopia. Clin Exp Allergy 34: 779–785PubMedCrossRefGoogle Scholar
  9. 9.
    Naleway AL, Belongia EA, Greenlee RT et al. (2003) Eczematous skin disease and recall of past diagnoses: implications for smallpox vaccination. Ann Intern Med 139: 1–7PubMedGoogle Scholar
  10. 10.
    Vichyanond P, Sunthornchart S, Singhirannusorn V et al. (2002) Prevalence of asthma, allergic rhinitis and eczema among university students in Bangkok. Respir Med 96: 34–38PubMedCrossRefGoogle Scholar
  11. 11.
    Illi S, von Mutius E, Lau S et al. (2004) The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 113: 925–931PubMedCrossRefGoogle Scholar
  12. 12.
    Kissling S, Wüthrich B (1993) Verlauf der atopischen Dermatitis nach dem Kleinkindalter. Hautarzt 44: 569–573PubMedGoogle Scholar
  13. 13.
    Rystedt I (1985) Long term follow-up in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 114: 117–120Google Scholar
  14. 14.
    Schmitt J, Csotonyi F, Bauer A, Meurer M (2008) Determinants of treatment goals and satisfaction of patients with atopic eczema. J Dtsch Dermatol Ges 6: 458–465PubMedCrossRefGoogle Scholar
  15. 15.
    Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. (2006) Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38: 441–446PubMedCrossRefGoogle Scholar
  16. 16.
    Steinert PM, Cantieri JS, Teller DC et al. (1981) Characterization of a class of cationic proteins that specifically interact with intermediate filaments. Proc Natl Acad Sci USA 78: 4097–4101PubMedCrossRefGoogle Scholar
  17. 17.
    Candi E, Schmidt R, Melino G (2005) The corniefied envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 6: 328–340PubMedCrossRefGoogle Scholar
  18. 18.
    Baurecht H, Irvine AD, Novak N et al. (2007) Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 120: 1406–1412PubMedCrossRefGoogle Scholar
  19. 19.
    Barker JN, Palmer CN, Zhao Y et al. (2007) Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol 127: 564–567PubMedCrossRefGoogle Scholar
  20. 20.
    Röckl H (1972) Das nummuläre und das mikrobielle Ekzem. Hautarzt 23: 326–330PubMedGoogle Scholar
  21. 21.
    Aoyama H, Tanaka M, Hara M, Tagami H (1999) Nummular eczema: an addition of senile xerosis and unique cutaneous reactivities to environmental aeroallergens. Dermatology 199: 135–139PubMedCrossRefGoogle Scholar
  22. 22.
    Hald M, Berg ND, Elberling J, Johansen JD (2008) Medical consultations in relation to severity of hand eczema in the general population. Br J Dermatol 158: 773–777PubMedCrossRefGoogle Scholar
  23. 23.
    Dickel H, Bruckner TM, Schmidt A, Diepgen TL (2003) Impact of atopic skin diathesis on occupational skin disease incidence in a working population. J Invest Dermatol 121: 37–40PubMedCrossRefGoogle Scholar
  24. 24.
    Bandmann H-J, Agathos M (2008) Die atopische Handdermatitis. Hautarzt 28: 110–113Google Scholar
  25. 25.
    Svensson A (1988) Hand eczema: an evalutation of the frequency of atopic background and the difference in clinical pattern between patients with and without atopic dermatitis. Acta Derm Venereol (Stockh) 68: 509–513Google Scholar
  26. 26.
    Lerbaek A, Bisgaard H, Agner T et al. (2007) Filaggrin null alleles are not associated with hand eczema or contact allergy. Br J Dermatol 157: 1199–1204PubMedCrossRefGoogle Scholar
  27. 27.
    Diepgen TL, Pilz B, Schmidt A et al. (1993) Berufsbedingte Hauterkrankungen bei Auszubildenden im Friseur- und Krankenpflegeberuf. Konzept einer prospektiven Längsschnittstudie. Allergologie 10: 369–403Google Scholar
  28. 28.
    Funke U, Diepgen T, Fartasch M (1996) Risk-group-related prevention of hand eczema at the workplace. Curr Probl Dermatol 25: 123–132PubMedGoogle Scholar
  29. 29.
    Dickel H, Kuss O, Schmidt A et al. (2001) Incidence of occupation-related skin diseases in skin-exposure occupational groups. Hautarzt 52: 615–623PubMedCrossRefGoogle Scholar
  30. 30.
    Bauer A, Bartsch R, Stadeler M et al. (1998) Development of occupational skin diseases during vocational training in baker and confectioner apprentices: a follow-up study. Contact Dermatitis 39: 307–311PubMedCrossRefGoogle Scholar
  31. 31.
    Bauer A, Elsner P (1999) The environment and the skin. Curr Probl Dermatol 28: 153–160PubMedCrossRefGoogle Scholar
  32. 32.
    Lammintausta K, Kalimo K (1981) Atopy and hand dermatitis in hospital wet work. Contact Dermatitis 7: 301–308PubMedCrossRefGoogle Scholar
  33. 33.
    Rystedt I (1985) Hand eczema in patients with history of atopic manifestations in childhood. Acta Derm Venereol (Stockh) 65: 305–312Google Scholar
  34. 34.
    Coenraads PJ, Diepgen TL (1998) Risk for hand eczema in employees with past or present atopic dermatitis. Int Arch Occup Environ Health 71: 7–13PubMedCrossRefGoogle Scholar
  35. 35.
    Bauer A, Kelterer D, Stadeler M et al. (2001) The prevention of occupational hand dermatitis in bakers, confectioners and employees in the catering trades. Preliminary results of a skin prevention program. Contact Dermatitis 44: 85–88PubMedCrossRefGoogle Scholar
  36. 36.
    Freeman AF, Holland SM (2008) The hyper-IgE syndromes. Immunol Allergy Clin North Am 28: 277–291, viiiPubMedCrossRefGoogle Scholar
  37. 37.
    Ong PY, Ohtake T, Brandt C et al. (2002) Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347: 1151–1160PubMedCrossRefGoogle Scholar
  38. 38.
    Howell MD, Wollenberg A, Gallo RL et al. (2006) Cathelicidiin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 117: 836–841PubMedCrossRefGoogle Scholar
  39. 39.
    Wollenberg A, Zoch C, Wetzel S et al. (2003) Predisposing factors and clincial features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 49: 198–205PubMedCrossRefGoogle Scholar
  40. 40.
    Ellis C, Luger T, Abeck D et al. (2003) International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol (Suppl 63) 148: 3–10Google Scholar
  41. 41.
    Luger TA, Bieber T, Meurer M et al. (2004) Therapie des atopischen Ekzems mit Calcineurin-Inhibitoren. Leitlinie der Deutschen Dermatologischen Gesellschaft (DDG) und des Berufsverbandes Deutscher Dermatologen (BVDD). http://www.uni-duesseldorf.de/awmf/ll-na/013–037.htmGoogle Scholar
  42. 42.
    Williams HC (2005) Clinical practice. Atopic dermatitis. N Engl J Med 352: 2314–2324PubMedCrossRefGoogle Scholar
  43. 43.
    Atherton DJ (2003) Topical corticosteroids in atopic dermatitis. BMJ 327: 942–943PubMedCrossRefGoogle Scholar
  44. 44.
    Furue M, Terao H, Rikihisa W et al. (2003) Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 148: 128–133PubMedCrossRefGoogle Scholar
  45. 45.
    Meurer M, Fartasch M, Albrecht G et al. (2004) Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 208: 365–372PubMedCrossRefGoogle Scholar
  46. 46.
    Büchau AS, Schauber J, Au N et al. (2008) Pimecrolimus enhances innate immune function of normal human keratinocytes. J Invest Dermatol 127: S127Google Scholar
  47. 47.
    Schauber J, Gallo RL (2008) The vitamin D pathway: a new target for control of the skin’s immune response? Exp Dermatol 17: 633–639PubMedCrossRefGoogle Scholar
  48. 48.
    Krutmann J (2000) Phototherapy for atopic dermatitis. Clin Exp Dermatol 25: 552–558PubMedCrossRefGoogle Scholar
  49. 49.
    Hölzle E, Hönigsmann H, Röcken M et al. (2002) Empfehlungen der Deutschen Dermatologischen Gesellschaft (DDG). Empfehlungen zur Phototherapie und Photochemotherapie. www.leitlinien.net. Arbeitsgemeinschaft der wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). 20-2-2008Google Scholar
  50. 50.
    Der-Petrossian M, Seeber A, Honigsmann H, Tanew A (2000) Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. Br J Dermatol 142: 39–43PubMedCrossRefGoogle Scholar
  51. 51.
    Tzaneva S, Seeber A, Schwaiger M et al. (2001) High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 45: 503–507PubMedCrossRefGoogle Scholar
  52. 52.
    Armstrong BK, Kricker A (2001) The epidemiology of UV induced skin cancer. J Photochem Photobiol B 63: 8–18PubMedCrossRefGoogle Scholar
  53. 53.
    Schmitt J, Schmitt NM, Meurer M (2007) Cyclosporin in the treatment of patients with atopic eczema – a systematic review and meta-analysis. JEADV 21: 606–619PubMedGoogle Scholar
  54. 54.
    Schmitt J, Schakel K, Schmitt N, Meurer M (2007) Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol 87: 100–111PubMedCrossRefGoogle Scholar
  55. 55.
    Marcil I, Stern RS (2001) Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 358: 1042–1045PubMedCrossRefGoogle Scholar
  56. 56.
    Behnam SM, Behnam SE, Koo JY (2005) Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol 4: 189–194PubMedGoogle Scholar
  57. 57.
    Hanifin JM, Schneider LC, Leung DY et al. (1993) Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 28: 189–197PubMedCrossRefGoogle Scholar
  58. 58.
    Berth-Jones J, Takwale A, Tan E et al. (2002) Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 147: 324–330PubMedCrossRefGoogle Scholar
  59. 59.
    Grundmann-Kollmann M, Podda M, Ochsendorf F et al. (2001) Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 137: 870–873PubMedGoogle Scholar
  60. 60.
    Neuber K, Schwartz I, Itschert G, Dieck AT (2000) Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 143: 385–391PubMedCrossRefGoogle Scholar
  61. 61.
    Paul C, Lahfa M, Bachelez H et al. (2002) A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 147: 518–522PubMedCrossRefGoogle Scholar
  62. 62.
    Jacobi A, Antoni C, Manger B et al. (2005) Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52: 522–526PubMedCrossRefGoogle Scholar
  63. 63.
    Schmitt J, Wozel G, Pfeiffer C (2004) Leflunomide as a novel treatment option in severe atopic dermatitis. Br J Dermatol 150: 1182–1185PubMedCrossRefGoogle Scholar
  64. 64.
    Schmitt J, Schakel K (2007) Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit. Hautarzt 58: 128, 130–128, 132PubMedCrossRefGoogle Scholar
  65. 65.
    Bär M, Schmitt J, Bauer A et al. (2008) Successful treatment of an elderly patient with refractory UVA-sensitive atopic eczema with mycophenolic acid. Acta Derm Venereol 88: 404–405PubMedGoogle Scholar
  66. 66.
    Andersen KE (2005) Atopic hand eczema and treatment strategies. Acta Derm Venereol Suppl (Stockh) 6: 45–48CrossRefGoogle Scholar
  67. 67.
    Diepgen TL, Svensson A, Coenraads PJ (2005) Therapy of hand eczema. What can we learn from the published clinical studies? Hautarzt 56: 224–231PubMedCrossRefGoogle Scholar
  68. 68.
    Ruzicka T, Lynde CW, Jemec GB et al. (2008) Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 158: 808–817PubMedCrossRefGoogle Scholar
  69. 69.
    Mischke D, Korge BP, Marenholz I et al. (1996) Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex („epidermal differentiation complex“) on human chromosome 1q21. J Invest Dermatol 106: 989–992PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2008

Authors and Affiliations

  1. 1.Klinik und Poliklinik für DermatologieUniversitätsklinikum Carl Gustav Carus der Technischen Universität DresdenDresdenDeutschland

Personalised recommendations